Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Treatment Sequencing of Later Line Therapies in R/R DLBCL

February 20th 2024

With the emergence of newer agents, panelists discuss their approaches to best sequence treatments for patients with R/R DLBCL.

Bridging Therapy With CAR T-Cell Therapy in LBCL

February 20th 2024

Caron A. Jacobson, MD, and Miguel-Angel Perales, MD, discuss different uses for CAR T-cell therapy, particularly a trial in which a CAR T-Cell therapy is being evaluated in MRD-positive patients treated with chemotherapy.

Future Directions and Unmet Needs in Relapsed/Refractory MCL

February 20th 2024

A panel of experts discuss future directions and remaining unmet needs for patients with relapsed/refractory MCL.

The Impact of Real-World Analyses in the Utilization of CAR T-Cell Therapy in LBCL

February 20th 2024

Thought leaders discuss patient scenarios and different factors to consider when deciding how to select and utilize bridging therapy in the management of patients with LBCL.

Treating VOD: Standard-of-Care Approach

February 19th 2024

Mitchell Cairo, MD, shares his standard-of-care approach to treating VOD and the role of defibrotide, the only FDA-approved drug for VOD.

A Multidisciplinary Approach to Managing VOD

February 19th 2024

Sergio Giralt, MD, leads a discussion on the importance of a multidisciplinary team approach in caring for patients with VOD, from recognizing early signs to treating and monitoring the disease.

Bispecific Antibodies and Noncovalent BTK Inhibitors Expand Horizons in DLBCL and MCL

February 18th 2024

Catherine C. Coombs, MD, spotlights the use of bispecific antibodies in diffuse large B-cell lymphoma and pirtobrutinib in mantle cell lymphoma.

Hematologists and Patients Come Together for Patient-Focused GVHD Discussions

February 17th 2024

Carrie L. Kitko, MD, and Sagar S. Patel, MD, discuss recent treatment developments and ongoing unmet needs in the graft-vs-host treatment paradigm.

Emerging Therapies for the Older Patient With Acute Lymphoblastic Leukemia

February 16th 2024

Dr. Shah and faculty provide updates on emerging therapies, which exhibit promise for the treatment of relapsed or refractory acute lymphoblastic leukemia such as tisagenlecleucel and Obe-cel; obecabtagene autoleucel, preliminary outcomes of which were presented in the FELIX study at the 65th ASH Annual Meeting.

Optimal Sequencing of Therapy for Previously Treated Patients With Relapsed or Refractory ALL

February 16th 2024

Dr. Shah and colleagues dissect the social determinants of health, including limited personal resources, frailty, distance to treatment facilities, therapeutic compliance, and other considerations that impact effective treatment sequencing for patients with relapsed or refractory ALL, including access to care and CAR-T cell availability.

The Role of Allo-HSCT in Higher-Risk MDS

February 16th 2024

Criteria for identifying patients with MDS most likely to benefit from transplant and choosing the optimal donor source and conditioning regimen on a case-by-case basis.

Future of MF

February 16th 2024

Experts discuss how treatments, either monotherapy or combination, may impact the treatment landscape for MF and how they might choose among the new agents.

Toxicity Assessment of Precision-Engineered Allo-HSCT

February 16th 2024

Safety and toxicity data from a clinical trial investigating a novel, precision-engineered allo-HSCT conditioning regimen for older patients with high-risk blood cancers.

Third Line Treatment in Chronic GVHD

February 15th 2024

Drs Yi-Bin Chen, Corey Cutler, Hannah Choe, and Mitchell Horwitz discuss a complex chronic GVHD case post-allogeneic transplant. The panel explores third-line options, including belumosudil, ibrutinib, photopheresis, and clinical trials, emphasizing shared decision-making and the need for well-designed trials in guiding treatment decisions.

A GVHD Clinical Scenario

February 15th 2024

Drs Yi-Bin Chen, Corey Cutler, Hannah Choe, and Mitchell Horwitz review a clinical scenario of chronic GVHD post-allogeneic transplant. They explore treatment options and emphasize shared decision-making, considering patient preferences and therapeutic benefits.

Recent Approvals Across Hematologic Malignancies Usher in a New Era

February 14th 2024

Mikkael A. Sekeres, MD, MS, highlights recent approvals and emerging therapeutics in hematologic malignancies discussed by his colleagues.

Patient Profile 2: A 77-Year-Old Man With MDS

February 14th 2024

The expert panel provides comprehensive insights on another patient case, a 77-year-old with MDS who presented with symptomatic anemia.

Second-Line Treatment of Lower-Risk MDS With Symptomatic Anemia

February 14th 2024

Continuing their discussion on the first patient profile, the expert panel focuses on the second-line treatment of patients with lower-risk MDS and symptomatic anemia.

Standard-of-Care Drugs Provide Strong Foundation For Effective Combinations in Hematologic Malignancies

February 13th 2024

Catherine C. Coombs, MD, discusses future directions for BTK inhibitors in chronic lymphocytic leukemia and combination therapies in myelofibrosis.

FDA Accepts NDA Resubmission for Dasynoc in CML

February 13th 2024

A new drug application for Dasynoc, a protein kinase inhibitor product candidate for patients with chronic myeloid leukemia, has been accepted by the FDA.